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men, (in different study settings is more frequent 
in women). AIDS clinical-immunological status is 
associated with increased risk of anemia. Lower 
CD4 ceil counts are [inked to higher rate of ane- 
mia. The rate of anemia went down when patients 
started using ART. However, ART has not eliminated 
anemia; there was an increased rate in patients 
whose ART regimen contained ZDV. 
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Background: HIV-1/HIV-2 co-infection is infre- 
quently encountered. It was suggested that HIV-2 
has a protective effect with regards to subsequent 
HIV-1 superinfection. 
Objective: To describe a we[[ documented case of 
HIV-1 superinfection in a previously HIV-2 mono- 
infected woman. 
Methods: Diagnostic assays used: HIV-1 and -2- 
specific antibodies: ELISA (screening), Western blot 
analysis (Gene[abs Diagnostics), or line immuno- 
assay (INNOLIA, Innogenetics). HIV-1-RNA: COBAS 
Amp[icor H IV Monitor assay. Retrospective analyses 
of HIV-1 -RNA in plasma or provira[ DNA in PBMC: in- 
house real-time PCR with primers in gag and poL 
HIV-2-RNA or-DNA RT-PCR: PCR with primers in LTR 
and gag. RT-activity: u[trasensitive PERT assay. 
Results (case report): In 12/01 a 1962 born woman 
from Benin presented with preterm contractions. 
HIV-1 and -2 screening tests were both reactive. 
Western blot revealed a positive result for HIV-2 
but a negative one for HIV-1. HIV-1 and HIV-2 
plasma RNA were undetectab[e. In 1/02 assays 
were repeated and confirmed. Baseline CD4 count 
was 729 ceils/u[ (48%). The child was born by cae- 
sarean section in 12/01 in the absence of antiretro- 
viral treatment but remained HIV negative. In 5/02 
CD4 count suddenly dropped to 340 (26%). Now, 
HIV-1 plasma RNA was detectable (540copies/m[) 
and Western blot for HIV-1 was unambiguously 
positive. HIV-RNA increased to 1760copies/m[ in 
10/02 and spontaneously dropped to 63copies/m[ 
in 1/05. CD4 count rose to 578 (27%). No HIV associ- 
ated disease developed. HIV-1 provira[ DNA amplifi- 
cations for gag and po[ were positive. Phy[ogenetic 
analysis revealed most likely a subtype A virus. 
HIV-2 plasma RNA and provira[ DNA remained unde- 
tectab[e despite different attempts using different 
primer pairs. In summary, HIV-I seroconversion be- 
tween 1102 and 5102 was clearly demonstrated by 
newly emerging antibodies against TM and SU env 
antigens of HIV-I in the INNOLIA assay. 
Conclusion: Here, we demonstrate a rare case of 
a chronically HIV-2 infected individual who was 
superinfected by HIV-I. The benign course of the 
HIV-I infection with almost undetectab[e HIV-I 
RNA in the absence of antiretrovira[ treatment may 
be the consequence of a potential immunoprotec- 
tive effect induced by HIV-2 against HIV-I or by 
virat interference at the co-receptor [eve[. 
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Background: Sexual transmission of human immun- 
odeficiency virus type 1 (HIV-1) is not very ef- 
ficient (approximately 0.1% per coitus), although 
frequent exposure to genital secretions such as 
semen ultimately leads to successful transmission 
of HIV-1 that is almost exclusively R5 (macrophage- 
tropic) phenotype. Semen contains macrophages 
and [ymphocytes, and dendritic ceils are consid- 
ered to be the first target of HIV-1 in the recessive 
genital/rectal mucosa. 
Objectives: To explore seminal fluid effects on 
HIV-1 infection of [ymphocytes, monocyte-derived 
macrophages (MDM) or monocyte-derived endritic 
ceils (MDDC) in vitro. 
Methods: HIV-1 infection of the respective ceils 
was investigated by single- or multiple-round viral 
replication assays in the presence or absence of 
seminal fluid. Effects of seminal fluid on cytotoxi- 
city, ceil surface expression of CCRS, and activity 
of HIV-1 long terminal repeat (LTR) promoter were 
assessed by MTT assays, flow cytometry and tran- 
sient expression assays, respectively. HIV-1 neu- 
tralization assays were performed by inoculating 
HIV-1 stocks pretreated with seminal fluid onto 
MAGIC5 ceil mono[ayer. HIV-1 transmission assays 
were performed by pulsing AZT-treated MDDC by 
HIV-1 in the presence or absence of seminal fluid, 
cocu[turing them with [ymphocytes, and quantitat- 
ing provira[ DNA by real time PCR. 
Results: Seminal fluid was toxic to [ymphocytes and 
inhibited HIV-1 infection of activated [ymphocytes. 
On the other hand, seminal fluid rather supported 
MDM cultures and had dichotomous effects on HIV-1 
infection of MDM: it inhibited an early step of HIV-1 
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infection by downregutating celt surface CCR5 ex- 
pression and enhanced HIV-1 expression by transac- 
tivating HIV-1 LTR promoter. ProstagLandin E2, one 
of the major constituents of seminal fluid, exerted 
similar effects on HIV-1 infection of MDM. Semi- 
hal fluid enhanced efficiency of HIV-1 transmission 
from MDDC to [ymphocytes, and such effect was 
diminished by anti-DC-SIGN antibody but not CCR5 
inhibitors. 
Conclusions: Differential effects of seminal fluid on 
[ymphocytes and MDM may favor accumulation of 
macrophage-derived RS-HIV-1 in semen; however, 
seminal fluid appears to help dendritic ceLLs in 
recessive genitaL/rectaL mucosa transmit HIV-1 to 
[ymphocytes, irreLevantLy to whether it is RS- or 
X4-HIV-1. 
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Background: To evaluate the impact of discontinu- 
ing Enfuvirtide (T-20) in heavily pretreated HIV-1- 
infected patients. 
Methods: Pts treated with T-20 between 4/2001- 
12/2004 within the Swiss HIV Cohort Study (SHCS). 
FoLLow-up until 2/2006. MuLtivariate analysis (Cox 
hazards modeL) in a subgroup of pts with baseline 
CD4 <200 ceLLs/pL who had been treated with T-20 
for >12 weeks. 
Results: 105 pts were analyzed. Most pts were 
male (89%), median age 44 (27-66), prior AIDS 67%, 
HCV 26%, intravenous drug use (IDU) 23%. Me- 
dian baseline VL was 4.9 Log~0 copies/mL and CD4 
84 cetts/mL. During foLLow-up 41/105 (39%) pts dis- 
continued T-20, due to the patient's wish (39%), vi- 
roLogicaL failure (19%), ART-toxicity (12%). Pts stop- 
ping T-20 had a more advanced isease at baseline 
compared to those who continued treatment (prior 
AIDS 77% versus 61%, CD4 49 versus 107). In the 
on-treatment analysis VL<400c/mL was achieved 
by 57/97 (59%), 48/77 (62%), 19/30 (63%) and 
9/14 (64%) pts after 24, 48, 96 and 144 weeks, 
respectively. In the intention-to-treat nalysis 56%, 
54%, 38% and 33% pts achieved VL<400 c/mL after 
24, 48, 96 and 144 weeks, respectively. After stop- 
ping T-20, 20% of 41 pts maintained VL<400c/mL 
after 12, 24 and 48 weeks. On treatment, a median 
CD4 increase of 63, 93, 147 and 108cetts/pL above 
baseline was observed at week 24, 48, 96 and 
144, respectively. After discontinuing T-20, CD4 
declined from 72 by 5, 16 and 15cetts/mL after 
12, 24 and 48 weeks, respectively. In a multivariate 
analysis of 74 pts with baseline CD4 <200 treated 
>12 weeks, higher CD4 at baseline was the only 
predictor of CD4 response *200 to T-20 (adjusted 
HR 4.26, 95%CI 2.25-8.08, p < 0.001). New AIDS- 
defining events occurred in 7/105 pts during treat- 
ment and in 10/41 pts after stopping T-20.6 pts 
died during treatment (4 HIV-retated); 17 after 
stopping T-20 (11 HIV-retated). 
Conclusions: Our data indicate that T-20 should 
not be initiated too Late. In most pts stopping T-20 
viremia is not controLLed and CD4 tend to decrease. 
Discontinuation of T-20 may be associated with a 
poorer prognosis. 
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Background: IsoLated toxopLasmic retinochoroidi- 
tis rarely occurs as first and soLeLy opportunistic 
infection in HIV positive patients. The benefit of 
treatment other than HAART is debated and there 
is no consensus for the best regimen. However, 
HAART can Lead to immune recovery vitritis, caus- 
ing therapeutic chaLLenges. 
Objective: We present a 34 year old HIV posi- 
tive man with a toxopLasmic retinochoroiditis and 
immune recovery vitritis after initiating HAART. 
Successful treatment included parabuLbar steroid 
injection. 
Methods: CD4 count and viral Load were examined 
in intervals of 3 months. Serial ophthaLmoLogic 
